Healthcare technology platform company PointClickCare announces RWD collaboration with Pfizer

PointClickCare Technologies and Pfizer will collaborate to unlock real-world insights to enhance understanding and care of under-represented long-term and post-acute care demographic.

PointClickCare Technologies, a leading healthcare technology platform, has recently announced a RWD collaboration with Pfizer Inc. Their mutual goal is to unlock real-world insights to enhance understanding and care of older adults at high risk of age-related disorders in long-term and post-acute care (LTPAC) facilities, an often overlooked and under-represented demographic.

“Real world evidence is at the root of an ongoing and critical transformation in health care. By analyzing real world data, we can learn more about a patient population. And those insights can help guide our decisions about developing new therapies.” stated Simon Dagenais, Senior Director of Pfizer’s RWE Center of Excellence.

Globally, the population is aging rapidly. Between 2015–2050, the proportion of the world’s population over age 60 will nearly double, from 12% to 22%. In the US, the number of individuals older than age 65 is projected to peak at 95 million in 2060. Older adults are at risk of developing age-related disorders such as loss of appetite, malnutrition, involuntary weight loss, and cachexia, which can lead to adverse health outcomes.

Although many older adults will need to spend time in a long-term care facility as they age, members of this portion of the population are often unable to participate in clinical trials. This lack of representation can limit the development of therapies aimed at addressing the unmet needs of this important demographic.

PointClickCare’s platform spans over 27,000 LTPAC providers and 2,700 hospitals, approaching 70% of all LTPAC facilities. With access to the RWD, and outcomes-based evidence through extensive longitudinal patient records that PointClickCare can provide, Pfizer’s R&D teams will be able to gain a deeper understanding of the health of older people in LTPAC facilities, resulting in more data-enriched clinical trials and empirical evidence-based studies. Pfizer’s Simon Dagenais expounded: “Access to data on comorbidities, medications, vital signs, body weight, and physical function in older adults residing in long-term care through electronic medical records is very important to help us design clinical trials for this patient population.”

“Our evidence-rich database can provide insights that specifically represent older adults in long-term care facilities —a population that is often overlooked — to support research by expanding drug discovery and development.” said Jeff Wessinger VP & GM of Life Sciences at PointClickCare. “We’re proud to support companies, like Pfizer, who are doing their part to accelerate research for this demographic and make trials more inclusive, to ultimately improve care outcomes.”